

Joerg Wenzel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4667031/publications.pdf>

Version: 2024-02-01

199
papers

8,922
citations

46984

47
h-index

53190

85
g-index

216
all docs

216
docs citations

216
times ranked

9399
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigallocatechinâ€“gallate exhibits antiâ€“inflammatory effects in a human interface dermatitis modelâ€“implications for therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 144-153.	1.3	8
2	Annular plaques mimicking Rowellâ€™s syndrome in the course of coronavirus disease 2019 mRNA vaccines: An overlooked phenomenon?. <i>Journal of Dermatology</i> , 2022, 49, 151-156.	0.6	9
3	Targeted Therapies in Autoimmune Skin Diseases. <i>Journal of Investigative Dermatology</i> , 2022, 142, 969-975.e7.	0.3	6
4	Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patientsâ€™ Focus on Clinical and Histopathological Variation. <i>Dermatopathology (Basel, Switzerland)</i> , 2022, 9, 60-81.	0.7	6
5	JAK1/2 inhibitor but not ILâ€“4 receptor alpha antibody suppresses allergenâ€“mediated activation of human basophils in vitro. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2253-2256.	2.7	1
6	Interferonâ€“beta as an enhancer of paraviral exanthema during influenza virus infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e228-e230.	1.3	0
7	JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2202-2212.e8.	1.5	20
8	Grzybowskiâ€™s Generalized Eruptive Keratoacanthomas in a Patient with Terminal Kidney Diseaseâ€“An Unmet Medical Need Equally Ameliorated by Topical Imiquimod Cream and Lapacho Tea Wraps: A Case Report. <i>Dermatology and Therapy</i> , 2021, 11, 625-638.	1.4	2
9	NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2021, 30, 847-852.	1.4	6
10	Efficacy and safety of treatment for Old World cutaneous leishmaniasis in pediatric patients: a case series. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1067-1073.	0.4	1
11	Exacerbation of subacute cutaneous lupus erythematosus following vaccination with <scp>BNT162b2 mRNA</scp> vaccine. <i>Dermatologic Therapy</i> , 2021, 34, e15017.	0.8	31
12	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus â€“ Part 2: Therapy, risk factors and other special topics. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1371-1395.	0.4	3
13	Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective. <i>Vaccines</i> , 2021, 9, 944.	2.1	67
14	Intercellular cGAMP transmission induces innate immune activation and tissue inflammation in Trex1 deficiency. <i>IScience</i> , 2021, 24, 102833.	1.9	3
15	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus â€“ Part 1: Classification, diagnosis, prevention, activity scores. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1236-1247.	0.4	8
16	Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines. <i>Dermatopathology (Basel, Switzerland)</i> , 2021, 8, 463-476.	0.7	24
17	S2kâ€“Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematosodes â€“ Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1371-1395.	0.4	2
18	Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study. <i>Experimental Dermatology</i> , 2021, 30, 1686-1692.	1.4	9
20	The Initial Stage of Neutrophilic Dermatitis of the Dorsal Hands: A Case Report and Discussion of Differential Diagnoses. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, 26-28.	0.1	0
21	Unusual flaccid blistering with mucosal involvement upon immune checkpoint inhibition. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 149-152.	0.4	2
22	Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept. <i>Journal of Dermatology</i> , 2020, 47, 397-401.	0.6	8
23	Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies. <i>Experimental Dermatology</i> , 2020, 29, 1123-1132.	1.4	6
24	Therapy-resistant erythema of the rima ani. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1518-1521.	0.4	0
25	Vitiligo-like depigmentation subsequent to subacute cutaneous lupus erythematosus and hydroxychloroquine treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1470-1473.	0.4	2
26	APRIL expression is upregulated in atopic dermatitis skin lesions and at sites of antigen driven allergic skin inflammation in mice. <i>Clinical Immunology</i> , 2020, 219, 108556.	1.4	1
27	The Proinflammatory Cytokine IL-36 ^β Is a Global Discriminator of Harmless Microbes and Invasive Pathogens within Epithelial Tissues. <i>Cell Reports</i> , 2020, 33, 108515.	2.9	27
28	Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases—Implications for Therapeutic Approaches. <i>Cells</i> , 2020, 9, 2627.	1.8	24
29	Cutaneous leishmaniasis with multiple ulcerated lesions in an immunocompetent patient caused by <i>Leishmania major</i> . <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 625-627.	0.4	1
30	Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions. <i>Frontiers in Immunology</i> , 2020, 11, 344.	2.2	41
31	Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1451-1455.e13.	0.3	48
32	Travel-associated infectious skin diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 730-733.	0.4	2
33	Immunostimulatory Endogenous Nucleic Acids Perpetuate Interface Dermatitis—Translation of Pathogenic Fundamentals Into an In Vitro Model. <i>Frontiers in Immunology</i> , 2020, 11, 622511.	2.2	8
34	Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00144.	0.6	12
35	Osteoma Cutis and Calcinosis Cutis: "Similar but Different". <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, 28-31.	0.1	1
36	Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. <i>Nature Reviews Rheumatology</i> , 2019, 15, 519-532.	3.5	119

#	ARTICLE	IF	CITATIONS
37	Severity modeling of extreme insurance claims for tariffication. Insurance: Mathematics and Economics, 2019, 88, 77-92.	0.7	13
38	Altered Notch Signaling in Dowling-Degos Disease: Additional Mutations in POGlut1 and Further Insights into Disease Pathogenesis. Journal of Investigative Dermatology, 2019, 139, 960-964.	0.3	15
39	Lokalisierte Pityriasis rubra pilaris in der Schwangerschaft: Eine sehr seltene Sonderform mit therapeutischer Herausforderung. JDDG - Journal of the German Society of Dermatology, 2019, 17, 28-30.	0.4	0
40	Interleukin-36 in Infectious and Inflammatory Skin Diseases. Frontiers in Immunology, 2019, 10, 1162.	2.2	83
41	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.5	1,265
42	EF24 Suppresses Cholangiocellular Carcinoma Progression, Inhibits STAT3 Phosphorylation, and Induces Apoptosis via ROS-Mediated Oxidative Stress. Journal of Oncology, 2019, 2019, 1-13.	0.6	5
43	FRI0193...2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
44	FRI0192...A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
45	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus "An Ongoing Need for International Consensus and Collaborations. Journal of Investigative Dermatology, 2019, 139, 270-276.	0.3	18
46	Candida induces the expression of IL-36Î³ in human keratinocytes: implications for a pathogen-driven exacerbation of psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e403-e406.	1.3	13
47	Increased levels of lipocalin 2 in palmoplantar pustular psoriasis. Journal of Dermatological Science, 2018, 90, 68-74.	1.0	27
48	Tumour necrosis factor-Î±-inhibitor-induced neutrophilic folliculitis presenting with strong lesional expression of interleukin-36Î³. Clinical and Experimental Dermatology, 2018, 43, 458-459.	0.6	3
49	Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. Multiple Sclerosis Journal, 2018, 24, 1785-1787.	1.4	6
50	High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus. Experimental Dermatology, 2018, 27, 95-97.	1.4	32
51	Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin. Cancer Research, 2018, 78, 5917-5926.	0.4	40
52	Detection of IL-36Î³ through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema. Journal of Allergy and Clinical Immunology, 2018, 142, 988-991.e4.	1.5	25
53	Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2â€chlorodeoxyadenosine: case report and review of the literature. British Journal of Dermatology, 2017, 176, 481-487.	1.4	21
54	Lipocalinâ€2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. British Journal of Dermatology, 2017, 177, 1385-1393.	1.4	73

#	ARTICLE	IF	CITATIONS
55	The role of histological presentation in erythroderma. International Journal of Dermatology, 2017, 56, 400-404.	0.5	9
56	<scp>JAK</scp> inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. Experimental Dermatology, 2017, 26, 728-730.	1.4	42
57	Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2017, 137, 1484-1492.	0.3	62
58	Applications of the central limit theorem for pricing Cliquet-style options. European Actuarial Journal, 2017, 7, 465-480.	0.5	8
59	Expression of the autoantigen TRIM33/TIF1 ^β in skin and muscle of patients with dermatomyositis is upregulated, together with markers of cellular stress. Clinical and Experimental Dermatology, 2017, 42, 659-662.	0.6	20
60	Mutations in ^β -secretase subunitâ€‘encoding PSENEN underlie Dowling-Degos disease associated with acne inversa. Journal of Clinical Investigation, 2017, 127, 1485-1490.	3.9	73
61	Biomarkers for psoriasis skin lesions. Italian Journal of Dermatology and Venereology, 2017, 152, 441-446.	0.1	1
62	Interleukin-36 ^β (IL-1F9) Identifies Psoriasis Among Patients With Erythroderma. Acta Dermato-Venereologica, 2016, 96, 386-387.	0.6	14
63	Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1165-1170.	1.3	43
64	Spleen tyrosine kinase (<scp>SYK</scp>) is a potential target for the treatment of cutaneous lupus erythematosus patients. Experimental Dermatology, 2016, 25, 375-379.	1.4	26
65	German guidelines for the diagnosis and therapy of localized scleroderma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 199-216.	0.4	97
66	Resistance to water and abrasion of a broad-spectrum sunscreen: a prospective, open-label study. Experimental Dermatology, 2016, 25, 151-152.	1.4	4
67	A wideband single-PLL RF receiver for simultaneous multi-band and multi-channel digital car Radio reception. , 2016, , .		5
68	A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. Journal of Nanobiotechnology, 2016, 14, 57.	4.2	42
69	Advances in the treatment of cutaneous lupus erythematosus. Lupus, 2016, 25, 830-837.	0.8	26
70	Upcoming therapeutic targets in cutaneous lupus erythematosus. Expert Review of Clinical Pharmacology, 2016, 9, 567-578.	1.3	19
71	Lupus erythematosus revisited. Seminars in Immunopathology, 2016, 38, 97-112.	2.8	48
72	Deutsche Leitlinie zur Diagnostik und Therapie der zirkumskripten Sklerodermie. JDDG - Journal of the German Society of Dermatology, 2016, 14, e1.	0.4	11

#	ARTICLE	IF	CITATIONS
73	JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1281-1283.	0.3	68
74	Entzündliche Dermatosen mit Interface-Dermatitis. , 2016, , 127-151.		0
75	A novel KRT86 mutation in a Turkish family with monilethrix, and identification of maternal mosaicism. <i>Clinical and Experimental Dermatology</i> , 2015, 40, 781-785.	0.6	7
76	Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2015, 24, 510-515.	1.4	66
77	Acknowledging the Clinical Heterogeneity of Lupus Erythematosus. , 2015, , 121-134.		0
78	More on Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib. <i>New England Journal of Medicine</i> , 2015, 372, 1273-1274.	13.9	9
79	Clinical and Molecular Implications of MED15 in Head and Neck Squamous Cell Carcinoma. <i>American Journal of Pathology</i> , 2015, 185, 1114-1122.	1.9	21
80	IL-36 β (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1025-1032.	0.3	211
81	Entzündliche Dermatosen mit Interface-Dermatitis. , 2015, , 1-37.		0
82	Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2014, 23, 516-518.	1.4	67
83	Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib. <i>New England Journal of Medicine</i> , 2014, 371, 2537-2538.	13.9	128
84	Photosensitivity, Apoptosis, and Cytokines in the Pathogenesis of Lupus Erythematosus: a Critical Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2014, 47, 148-162.	2.9	93
85	Low-dose methotrexate - a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris. <i>Dermatologic Therapy</i> , 2014, 27, 55-59.	0.8	2
86	Mutations in POGlut1, Encoding Protein O-Glucosyltransferase 1, Cause Autosomal-Dominant Dowling-Degos Disease. <i>American Journal of Human Genetics</i> , 2014, 94, 135-143.	2.6	136
87	Innate Immune-Response Mechanisms in Dermatomyositis: An Update on Pathogenesis, Diagnosis and Treatment. <i>Drugs</i> , 2014, 74, 981-998.	4.9	29
88	Role of High-Resolution Ultrasound and PET/CT Imaging for Preoperative Characterization of Sentinel Lymph Nodes in Cutaneous Melanoma. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 30-36.	0.7	29
89	Oxidative Damage of DNA Confers Resistance to Cytosolic Nuclease TREX1 Degradation and Potentiates STING-Dependent Immune Sensing. <i>Immunity</i> , 2013, 39, 482-495.	6.6	338
90	Nitrosative stress: a hallmark of the junctional inflammation in cutaneous lupus erythematosus. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 96-97.	0.6	13

#	ARTICLE	IF	CITATIONS
91	Phymatous Transformation of Facial Cutaneous Vascular Malformations: Clues to Phyma Pathogenesis. <i>JAMA Dermatology</i> , 2013, 149, 368.	2.0	1
92	Lupus tumidus following the lines of Blaschko. <i>International Journal of Dermatology</i> , 2013, 52, 1615-1617.	0.5	5
93	Real-Time Tissue Elastography as Promising Diagnostic Tool for Diagnosis of Lymph Node Metastases in Patients with Malignant Melanoma: A Prospective Single-Center Experience. <i>Dermatology</i> , 2013, 226, 81-90.	0.9	38
94	Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsis. <i>EMBO Journal</i> , 2012, 31, 201-213.	3.5	33
95	Suppression of UV-induced damage by a liposomal sunscreen: a prospective, open-label study in patients with cutaneous lupus erythematosus and healthy controls. <i>Experimental Dermatology</i> , 2012, 21, 958-961.	1.4	32
96	IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 426-433.e8.	1.5	229
97	Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00) Tj ETQq1 1 0.784314 rgBT /Overlo Imaging, 2012, 39, 581-588.	3.3	16
98	Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1316-1325.	3.3	8
99	Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. <i>Clinical and Experimental Dermatology</i> , 2012, 37, 139-142.	0.6	34
100	Diagnostics of autoimmune bullous diseases in German dermatology departments. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 492-499.	0.4	14
101	Indoleamine 2,3-dioxygenase expression in early keratocyte neoplasia of the lower lip correlates to the degree of cell atypia. <i>Pathology International</i> , 2012, 62, 105-111.	0.6	3
102	An Attempt at a Molecular Prediction of Metastasis in Patients with Primary Cutaneous Melanoma. <i>PLoS ONE</i> , 2012, 7, e49865.	1.1	13
103	Real time tissue elastography for diagnosis of cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 713-715.	0.6	4
104	Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus. <i>Lupus</i> , 2011, 20, 1300-1304.	0.8	34
105	PS1-030. Tyrosine kinase inhibitor SU6668 blocks the polyIC-induced IFN β -expression of keratinocytes: TBK1 as a potential drug-target for the treatment of cutaneous lupus erythematosus. <i>Cytokine</i> , 2011, 56, 24.	1.4	0
106	Indoleamine 2,3-dioxygenase-expressing myeloid dendritic cells and macrophages in infectious and noninfectious cutaneous granulomas. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 819-832.	0.6	21
107	Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 988-989.	0.6	28
108	Real-time tissue elastography: A helpful tool in the diagnosis of cutaneous melanoma?. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 424-426.	0.6	25

#	ARTICLE	IF	CITATIONS
109	Efficacy of Ablative Laser Treatment in Galli-Galli Disease. <i>Archives of Dermatology</i> , 2011, 147, 317.	1.7	15
110	Interferon- γ stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2011, 165, 1118-1123.	1.4	36
111	Malignant Peripheral Nerve Sheath Tumor of the Scalp: Case Report and Review of the Literature. <i>Dermatologic Surgery</i> , 2011, 37, 1684-1688.	0.4	8
112	New reasons for histopathological nail-clipping examination in the diagnosis of onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 235-237.	1.3	64
113	Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidence-based review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1385-1391.	1.3	52
114	Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2011, 20, 102-106.	1.4	25
115	P-Glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components. <i>Experimental Dermatology</i> , 2011, 20, 450-452.	1.4	33
116	Evidence for a Pathophysiological Role of Keratinocyte-Derived Type III Interferon (IFN λ) in Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2011, 131, 133-140.	0.3	110
117	High-Resolution Ultrasound Combined with Power Doppler Sonography Can Reduce the Number of Sentinel Lymph Node Biopsies in Cutaneous Melanoma. <i>Dermatology</i> , 2011, 222, 180-188.	0.9	14
118	Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma. <i>Histology and Histopathology</i> , 2011, 26, 997-1006.	0.5	12
119	Pyogenic granuloma-like lesion: a wolf in sheep's clothing. <i>European Journal of Dermatology</i> , 2011, 21, 121-122.	0.3	0
120	Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells. <i>British Journal of Dermatology</i> , 2010, 162, 870-874.	1.4	24
121	Systematic mutation screening of <i>KRT5</i> supports the hypothesis that Galli-Galli disease is a variant of Dowling-Degos disease. <i>British Journal of Dermatology</i> , 2010, 163, 197-200.	1.4	54
122	Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. <i>Nature Biotechnology</i> , 2010, 28, 943-949.	9.4	246
123	Bacteremia Caused by a Novel <i>Helicobacter</i> Species in a 28-Year-Old Man with X-Linked Agammaglobulinemia. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4672-4676.	1.8	17
124	Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. <i>Haematologica</i> , 2010, 95, 1697-1704.	1.7	55
125	Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. <i>Lupus</i> , 2010, 19, 1020-1028.	0.8	45
126	Ultrasound detection of PET/CT negative lymph node metastasis in cutaneous melanoma. <i>European Journal of Dermatology</i> , 2010, 20, 835-6.	0.3	1

#	ARTICLE	IF	CITATIONS
127	Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Archives of Dermatological Research, 2009, 301, 83-86.	1.1	62
128	IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. Journal of Clinical Investigation, 2009, 119, 47-60.	3.9	84
129	Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. International Journal of Cancer, 2008, 123, 2605-2615.	2.3	27
130	An IFN-Associated Cytotoxic Cellular Immune Response against Viral, Self-, or Tumor Antigens Is a Common Pathogenetic Feature in "Interface Dermatitis". Journal of Investigative Dermatology, 2008, 128, 2392-2402.	0.3	151
131	Gene Expression Profiling of Lichen Planus Reflects CXCL9+-Mediated Inflammation and Distinguishes this Disease from Atopic Dermatitis and Psoriasis. Journal of Investigative Dermatology, 2008, 128, 67-78.	0.3	68
132	Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 720-727.	2.7	143
133	Subacute cutaneous lupus erythematosus in a leuporelin-treated patient with prostate carcinoma. British Journal of Dermatology, 2008, 159, 231-233.	1.4	18
134	Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab. Clinical and Experimental Dermatology, 2008, 33, 347-348.	0.6	12
135	CXCR3 & ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. Journal of the American Academy of Dermatology, 2008, 58, 437-442.	0.6	36
136	Toll-Like Receptor-Agonists in the Treatment of Skin Cancer: History, Current Developments and Future Prospects. Handbook of Experimental Pharmacology, 2008, , 201-220.	0.9	12
137	IP10/CXCL10 - CXCR3 Interaction: a Potential Self-recruiting Mechanism for Cytotoxic Lymphocytes in Lichen Sclerosus et Atrophicus. Acta Dermato-Venereologica, 2007, 87, 112-117.	0.6	41
138	A Rapidly Growing Squamous Cell Carcinoma or Keratoacanthoma or Both?. Acta Dermato-Venereologica, 2007, 87, 447-448.	0.6	3
139	Successful Treatment of Bullous Congenital Ichthyosiform Erythroderma with Erythromycin. Dermatology, 2007, 215, 81-83.	0.9	1
140	Generalized Lichen Nitidus with Involvement of the Palms following Interferon Î± Treatment. Dermatology, 2007, 215, 236-239.	0.9	22
141	CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. Journal of the American Academy of Dermatology, 2007, 56, 648-650.	0.6	40
142	Tryptase detection in bone-marrow blood: A new diagnostic tool in systemic mastocytosis. Journal of the American Academy of Dermatology, 2007, 56, 453-457.	0.6	14
143	Indoleamine 2,3-Dioxygenase (IDO). American Journal of Pathology, 2007, 171, 1936-1943.	1.9	52
144	Kaposi's sarcoma of the gastrointestinal tract: Report of two cases and review of the literature. Pathology Research and Practice, 2007, 203, 227-231.	1.0	29

#	ARTICLE	IF	CITATIONS
145	The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. <i>British Journal of Dermatology</i> , 2007, 157, 752-757.	1.4	120
146	Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. <i>Experimental Dermatology</i> , 2007, 16, 454-463.	1.4	73
147	Loss-of-Function Mutations in the Keratin 5 Gene Lead to Dowling-Degos Disease. <i>American Journal of Human Genetics</i> , 2006, 78, 510-519.	2.6	238
148	Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation. <i>American Journal of Pathology</i> , 2006, 169, 665-672.	1.9	53
149	Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 930-937.	1.5	335
150	Type I interferon-associated cytotoxic inflammation in lichen planus. <i>Journal of Cutaneous Pathology</i> , 2006, 33, 672-678.	0.7	107
151	Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. <i>Clinical and Experimental Dermatology</i> , 2006, 31, 576-582.	0.6	113
152	Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. <i>British Journal of Dermatology</i> , 2006, 155, 861-862.	1.4	26
153	Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against autochthonous melanomas in the skin. <i>International Journal of Cancer</i> , 2006, 118, 373-380.	2.3	12
154	Treatment of Recalcitrant Dermatomyositis with Efalizumab. <i>Acta Dermato-Venereologica</i> , 2006, 86, 254-255.	0.6	24
155	Therapeutic Efficacy of Antigen-Specific Vaccination and Toll-Like Receptor Stimulation against Established Transplanted and Autochthonous Melanoma in Mice. <i>Cancer Research</i> , 2006, 66, 5427-5435.	0.4	59
156	Answer to the letter of Brockow et al. concerning our article "Safety of rush insect venom immunotherapy. Results of a retrospective study in 178 patients". <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 127-127.	2.7	2
157	Role of granulocyte elastase and interleukin-6 in the diagnosis of male genital tract inflammation. <i>Andrologia</i> , 2005, 37, 188-194.	1.0	97
158	Circulating clonal CLA+ and CD4+ T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. <i>British Journal of Dermatology</i> , 2005, 152, 258-264.	1.4	105
159	Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. <i>British Journal of Dermatology</i> , 2005, 153, 157-162.	1.4	123
160	Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. <i>British Journal of Dermatology</i> , 2005, 153, 1011-1015.	1.4	114
161	Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. <i>British Journal of Dermatology</i> , 2005, 153, 462-463.	1.4	33
162	Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sezary syndrome. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 702-706.	0.6	54

#	ARTICLE	IF	CITATIONS
163	Role of the Chemokine Receptor CCR4 and its Ligand Thymus- and Activation-Regulated Chemokine/CCL17 for Lymphocyte Recruitment in Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2005, 124, 1241-1248.	0.3	63
164	Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 257-262.	0.7	71
165	The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. <i>Experimental Dermatology</i> , 2005, 14, 454-459.	1.4	39
166	Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. <i>Journal of Pathology</i> , 2005, 205, 435-442.	2.1	202
167	Successful Rituximab Treatment of Severe Pemphigus Vulgaris Resistant to Multiple Immunosuppressants. <i>Acta Dermato-Venereologica</i> , 2005, -1, 1-1.	0.6	12
168	Letter to the Editor. <i>Lupus</i> , 2005, 14, 569-569.	0.8	4
169	Type I Interferon-associated Recruitment of Cytotoxic Lymphocytes. <i>American Journal of Clinical Pathology</i> , 2005, 124, 37-48.	0.4	88
170	The role of cytotoxic skin-homing CD8+ lymphocytes in cutaneous cytotoxic T-cell lymphoma and pityriasis lichenoides. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 422-427.	0.6	33
171	Keratitis-ichthyosis-deafness syndrome in association with follicular occlusion triad. <i>European Journal of Dermatology</i> , 2005, 15, 347-52.	0.3	46
172	Lymphocytopenia in lupus erythematosus: close in vivo association to autoantibodies targeting nuclear antigens. <i>British Journal of Dermatology</i> , 2004, 150, 994-998.	1.4	21
173	Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. <i>British Journal of Dermatology</i> , 2004, 150, 1194-1197.	1.4	35
174	Successful treatment of recalcitrant Wegener's granulomatosis of the skin with tacrolimus (Prograf TM). <i>British Journal of Dermatology</i> , 2004, 151, 927-928.	1.4	15
175	Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: Implications for the pathophysiology of vitiligo. <i>European Journal of Cell Biology</i> , 2004, 83, 797-803.	1.6	48
176	Bullous lupus erythematosus in a patient with pre-existing dermatomyositis. <i>Rheumatology International</i> , 2004, 24, 114-116.	1.5	3
177	Anti-cardiolipin antibodies in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 162-163.	2.7	4
178	Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 1176-1179.	2.7	34
179	Treatment of Dowling-Degos Disease With Er:YAG-Laser: Results After 2.5 Years. <i>Dermatologic Surgery</i> , 2003, 29, 1161-1162.	0.4	20
180	Indoleamine 2,3-dioxygenase-expressing antigen-presenting cells and peripheral T-cell tolerance. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 854-860.	1.5	26

#	ARTICLE	IF	CITATIONS
181	Treatment of Dowling-Degos Disease With Er. <i>Dermatologic Surgery</i> , 2003, 29, 1161-1162.	0.4	5
182	Granuloma Annulare Induced by Scabies. <i>Acta Dermato-Venereologica</i> , 2003, 83, 318-318.	0.6	8
183	Topical Treatment of Pyoderma gangraenosum. <i>Dermatology</i> , 2002, 205, 221-223.	0.9	55
184	FACS monitoring of lymphocyte-subsets in patients with discoid and subacute-cutaneous lupus erythematosus receiving low-dose methotrexate. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 216-220.	0.6	9
185	Successful Treatment of Chronic Discoid Lupus erythematosus of the Scalp with Imiquimod. <i>Dermatology</i> , 2002, 205, 416-418.	0.9	36
186	Periodic genital pruritus caused by syringoma of the vulva. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2002, 81, 369-370.	1.3	23
187	Successful Treatment of Dowling-Degos Disease with Er:YAG Laser. <i>Dermatologic Surgery</i> , 2002, 28, 748-750.	0.4	21
188	The value of lymphocytopenia as a marker of systemic involvement in cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2002, 146, 869-871.	1.4	17
189	Infraorbital eyelid edema as the presenting sign of bronchogenic carcinoma. <i>International Journal of Dermatology</i> , 2002, 41, 386-387.	0.5	5
190	Scleroderma and malignancy. Mechanisms of interrelationship. <i>European Journal of Dermatology</i> , 2002, 12, 296-300.	0.3	19
191	Flame Figures in Urticarial Lesions Accompanying Systemic Lupus Erythematosus. <i>American Journal of Dermatopathology</i> , 2001, 23, 533-535.	0.3	10
192	Antibodies targeting extractable nuclear antigens: historical development and current knowledge. <i>British Journal of Dermatology</i> , 2001, 145, 859-867.	1.4	28
193	Association of inclusion body myositis with subacute cutaneous lupus erythematosus. <i>Rheumatology International</i> , 2001, 21, 75-77.	1.5	14
194	Autoantibodies in Patients with Lupus erythematosus: Spectrum and Frequencies. <i>Dermatology</i> , 2000, 201, 283-283.	0.9	20
195	Presence of antinuclear antibodies in patients with lupus erythematosus is correlated with diminished T-helper cells. <i>British Journal of Dermatology</i> , 2000, 143, 1100-1101.	1.4	7
196	Discoid and subacute cutaneous lupus erythematosus: detection of differences in peripheral lymphocyte numbers. <i>Acta Dermato-Venereologica</i> , 2000, 80, 456.	0.6	1
197	Fluorescence-Activated Cell Sorter Analysis in Patients With Cutaneous Lupus Erythematosus. <i>Archives of Dermatology</i> , 1999, 135, 720-721.	1.7	3
198	Type I Interferon-Associated Recruitment of Cytotoxic LymphocytesA Common Mechanism in Regressive Melanocytic Lesions. , 0, .		3

#	ARTICLE	IF	CITATIONS
199	Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus. Frontiers in Medicine, 0, 9, .	1.2	10